Cagrilintide Australia: Research Overview

The short answer

Cagrilintide, also known by its development code AM833, is an investigational long-acting amylin analogue being studied by Novo Nordisk. It is a compound under clinical investigation, not an approved therapeutic good. In Australia it is not listed on the Australian Register of Therapeutic Goods (ARTG) and has not been approved by the Therapeutic Goods Administration (TGA) for any human use. On this basis NovaPeptides supplies cagrilintide strictly as a reference material for laboratory research only.

What cagrilintide is

Cagrilintide is a synthetic peptide described in the scientific literature as a long-acting analogue of human amylin. Amylin, also called islet amyloid polypeptide (IAPP), is a naturally occurring hormone co-secreted with insulin by the beta cells of the pancreas. An analogue is a laboratory-engineered molecule designed to resemble a natural compound while altering properties such as stability or duration of activity.

The development code AM833 (also written as NNC0174-0833) appears throughout the peer-reviewed and trial literature. The molecule was engineered with an acylation strategy intended to promote binding to plasma albumin, which the published medicinal-chemistry work associates with a prolonged half-life suitable for less frequent dosing in study settings. These are descriptions of the compound's design, not claims of any outcome.

How it is referred to in the literature

• Cagrilintide: the international non-proprietary name
• AM833 / NNC0174-0833: development codes used in trials and papers
• Amylin analogue: its mechanistic class
• Long-acting: its engineered pharmacokinetic profile as described by its developer

Mechanism as an amylin analogue

In the published research, cagrilintide is characterised as an agonist at amylin and calcitonin receptors. Amylin signalling involves the calcitonin receptor (CALCR) in combination with receptor activity-modifying proteins (RAMPs), which form the amylin receptor subtypes commonly described as AMY1 and AMY3. The research describes activity at receptors expressed in central nervous system regions associated with the amylin pathway.

This places cagrilintide in a different mechanistic class from the GLP-1 receptor agonists such as semaglutide. GLP-1 agonists act on the glucagon-like peptide-1 receptor, whereas amylin analogues engage the amylin and calcitonin receptor system. Because the two classes act through separate pathways, the scientific interest in combining them is a recurring theme in the literature. Nothing here should be read as a statement of clinical benefit.

Development and clinical-trial stage

Cagrilintide is investigational. According to the public trial record and its developer's disclosures, it has progressed through clinical studies but remains under investigation rather than approved as a standalone product. Much of the more recent development attention has centred on CagriSema, a fixed-combination of cagrilintide with the GLP-1 receptor agonist semaglutide.

The CagriSema programme includes large phase 3 clinical development programmes referenced in the public literature, including trials grouped under the REDEFINE name for studies in overweight or obesity, and REIMAGINE for studies in type 2 diabetes. Trial identifiers and protocols are catalogued on public registries such as ClinicalTrials.gov. The existence of these trials indicates active investigation and does not indicate marketing approval.

Regulatory filings and approval status change over time and differ by country. At the time of writing, cagrilintide as a standalone compound was not an approved medicine. Readers should treat any claim of approval with caution and verify current status against primary regulatory sources.

Australian regulatory status

In Australia, therapeutic goods are regulated by the TGA. A product generally must be entered on the ARTG before it can be lawfully supplied for therapeutic use. Cagrilintide is not entered on the ARTG and has not been approved by the TGA for any human therapeutic use.

Because it is not an approved therapeutic good, cagrilintide cannot be lawfully promoted, supplied, or used as a medicine in Australia. Where it is available at all, it is supplied as a research chemical and reference material for laboratory use by qualified researchers and institutions, not for human or animal administration. If you need to confirm the current scheduling of any substance under the Poisons Standard, consult the TGA directly rather than relying on third-party summaries.

Anti-doping context

Researchers and anyone connected to competitive sport should be aware that the World Anti-Doping Agency (WADA) maintains a Prohibited List that is updated annually and includes broad categories as well as named substances. Metabolic and peptide-hormone related compounds are an area WADA monitors closely. Because the list changes each year and category wording can capture investigational compounds, the only reliable approach is to check the current WADA Prohibited List and consult the relevant anti-doping authority. This page does not determine the status of cagrilintide for any sport.

What research use only means here

When NovaPeptides describes cagrilintide as research use only, it means the material is intended to be handled in a controlled laboratory environment by people qualified to do so. It is not a supplement, not a medicine, and not intended for consumption, injection, or any human or veterinary use.

Research-use framing in practice

• Intended for in-vitro and laboratory research by qualified personnel
• Not for human or animal administration or consumption
• Not a diagnosis, treatment, cure, or prevention of any condition
• Handled, stored, and disposed of in line with applicable laboratory safety and legal requirements

If you are researching this compound, rely on primary sources: peer-reviewed journals, the developer's official disclosures, and public trial registries. Treat marketing language from any vendor, including statements about outcomes, as something to verify independently.

Summary

Cagrilintide (AM833) is an investigational long-acting amylin analogue studied by Novo Nordisk, mechanistically distinct from GLP-1 receptor agonists and notably investigated as part of the CagriSema combination. It is at an investigational clinical stage, is not on the ARTG, and is not TGA-approved for human use in Australia. NovaPeptides references it only as a research-use-only material. For current regulatory and anti-doping status, always check primary sources such as the TGA and WADA.

Investigational status means a compound is still being studied. It is not a statement that the compound is safe, effective, or approved for any use.

Frequently asked questions